REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit

Investors allege Replimune Group built its RP1 regulatory strategy on single-arm trial designs and response criteria that the FDA had previously questioned as inconsistent with RECIST v1.1. The allegations create regulatory and litigation risk for RP1's approval pathway, potentially pressuring Replimune shares and investor confidence.